Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I

Pharmaceutical Research

Volumn 17, Issue 5, 2000, Pages 593-599

  Bhardwaj, Renu ^a   Hadley, Mac E ^b   Dorr, Robert T ^c   Dvorakova, Katarina ^c   Brooks, Christine ^b   Blanchard, James ^b  

^a GENZYME CORPORATION   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Controlled release; Melanogenesis; Melanotan I; Pharmacologic response; Poly (D,L Lactide co glycolide)

Indexed keywords

ALPHA INTERMEDIN DERIVATIVE; EUMELANIN; MELANIN; MELANOTAN 1; POLYGLACTIN; PYRROLE 2,3,5 TRICARBOXYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; FROG; GAMMA IRRADIATION; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MELANOGENESIS; NONHUMAN; PRIORITY JOURNAL; REFLECTOMETRY; SKIN CANCER; SKIN PIGMENTATION; ULTRAVIOLET RADIATION;

ALPHA-MSH; ANIMALS; ANTICARCINOGENIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG IMPLANTS; GUINEA PIGS; LACTIC ACID; MELANINS; POLYGLYCOLIC ACID; POLYMERS; PYRROLES; RANA PIPIENS; SKIN;

EID: 0034122581     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007525117894     Document Type: Article

References (23)

1. 1. C. Frey and A. Hartman. U.S. trends in melanoma incidence and mortality. J. Natl. Cancer Inst. 83:1705 (1991).
2. 2. B. A. Gilchrest, H. Y. Park, M. S. Eller, and M. Yaar. Mechanisms of ultraviolet light-induced pigmentation. Photochem. Photobiol. 63:1-10(1996).
3. 3. T. K. Sawyer, P. J. Sanfilippo, V. J. Hruby, M. H. Engel, C. B. Heward, J. B. Burnett, and M. E. Hadley. 4-Norleucine 7-D-phenylalanine-α-melanocyte-stimulating hormones, a highly potent α-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. USA 77:5754-5758 (1980).
4. 7]-α-MSH: a superpotent melanotropin with prolonged action on vertebrate chromatophores. Comp. Biochem. Physiol. 81:1-6(1985).
5. 5. S. O. Ugwu, J. Blanchard, R. T. Dorr, N. Levine, C. Brooks, M. E. Hadley, M. Aickin, and V. J. Hruby. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm. Drug Dispos. 18:259-269 (1997).
6. 6. R. Bhardwaj and J. Blanchard. In vitro characterization and in vivo release profile of a poly (D, L-lactide-co-glycolide)-based implant delivery system for the a-MSH analog, Melanotan-I. Int. J. Pharm. 170:109-1 17 (1998).
7. 7. K. Shizume, A. B. Lerner, and T. B. Fitzpatrick. In vitro bioassay for the melanocyte stimulating hormone. Endocrinology 54: 553-560 (1954).
8. 8. A. M. de La Castrucci, M. E. Hadley, and V. J. Hruby. Melanotropin bioassays: in vitro and in vivo comparisons. Gen. Comp. Endocrinol. 55:104-111 (1984).
9. 9. S. Ito and K. Fujita. Microanalysis of eumelanin and pheomelanin in hair and melanomas by chemical degradation and liquid chromatography. Anal. Biochem. 144:527-536 (1985).
10. 10. A. J. Thody, E. M. Higgins, K. Wakamatsu, S. Ito, S. A. Burchill, and J. M. Marks. Pheomelanin as well as eumelanin are present in human epidermis. J. Invest. Dermatol. 97:340-344 (1991).
11. 11. S. Ito and K. Wakamatsu. An improved modification of permanganate oxidation of eumelanin that gives a constant yield of pyrrole-2, 3, 5-tricarboxylic acid. Pigment Cell Res. 7:141-144 (1994).
12. 12. S. O. Ugwu, J. Blanchard, L. D. Nguyen, M. E. Hadley, and R. T. Dorr. A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. Biopharm. Drug Dispos. 15:383-390 (1994).
13. 13. J. L. Bolognia, M. S. Murray, and J. M. Pawelek. Hairless pigmented guinea pigs: A new model for the study of mammalian pigmentation. Pigment Cell Res. 3:150-156 (1990).
14. 14. K. Jimbow, W. C. Quevedo, Jr., T. B. Fitzpatrick, and G. Szabo. Some aspects of melanin biology. J. Invest. Dermatol. 67:72-89 (1976).
15. 15. G. Imokawa, M. Kawai, Y. Mishima, and I. Motegi. Differential analysis of experimental hypermelanosis by UVB, PUVA and allergic contact dermatitis using a brownish guinea pig model. Arch. Dermatol. Res. 278:352-362 (1986).
16. 16. J. Bolognia, M. Murray, and J. Pawelek. UVB-induced melanogenesis may be mediated through the MSH-receptor system. J. Invest. Dermatol. 92:651-656 (1989).
17. 17. R. S. Snell. The effect of ultraviolet irradiation on melanogenesis. J. Invest. Dermatol. 40:127-132 (1963).
18. 18. A. B. Lerner and S. S. McGuire. Effect of alpha and betamelanocyte stimulating hormones on the skin colour of man. Nature 189:176-179 (1961).
19. 19. J. T. Bagnara, J. D. Taylor, and M. E. Hadley. The dermal chromatophore unit. J. Cell. Biol. 38:67-79 (1968).
20. 20. M. E. Hadley. Endocrinology, 4th ed., Prentice Hall, Upper Saddle, NJ, 1996. pp. 153-176.
21. 21. J. Pawelek. Factors regulating the growth and pigmentation of melanoma cells. J. Invest. Dermatol. 66:201-209 (1976).
22. 22. K. Jimbow. Current update and trends in melanin pigmentation and melanin biology. Keio J. Med. 44:9-18 (1995).
23. 23. R. Bhardwaj and J. Blanchard. In vitro evaluation of Poly(D,L-lactide-co-glycolide) polymer-based implants containing the α-melanocyte stimulating hormone analog, Melanotan-I. J. Contr. Rel. 45:49-55 (1997).